Date:10/27/2009

Ended Ended Sept. Sept. (in thousands) 30, 2009 30, 2008 --------- --------- Clinical Research Services (CRS) Service revenue $202,324 $202,823 % of total service revenue 77.9% 77.1% Gross profit $73,042 $70,921 Gross margin % of service revenue 36.1% 35.0% PAREXEL Consulting & Medical Communications Services (PCMS) Service revenue $28,821 $30,111 % of total service revenue 11.1% 11.4% Gross profit $10,390 $9,948 Gross margin % of service revenue 36.1% 33.0% Perceptive Informatics, Inc. (PII) Service revenue $28,618 $30,112 % of total service revenue 11.0% 11.5% Gross profit $9,502 $10,813 Gross margin % of service revenue 33.2% 35.9% Total service revenue $259,763 $263,046 Total gross profit $92,934 $91,682 Gross margin % of service revenue 35.8% 34.9% Revenue by Geography -------------------- The Americas $101,601 $102,331 Europe, Middle East & Africa 129,540 140,387 Asia/Pacific 28,622 20,328 ------ ------ Total service revenue $259,763 $263,046 ======== ======== Quarterly Supplemental Financial Data -------------------------------------
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
2. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
3. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
4. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
5. PAREXEL Expands Global Clinical Pharmacology Capabilities
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
8. NxStage(R) Reports Significant Interim FREEDOM Study Results
9. Hospira Reports Third-Quarter 2009 Results
10. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
11. Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance